Impact of prognostic nutritional index on the recurrence of hepatocellular carcinoma after a curative resection.

BACKGROUNDS/AIMS: The purpose of this retrospective study was to determine the association between prognostic nutritional index (PNI) and recurrence of hepatocellular carcinoma after a curative resection.
METHODS: Between 2007 to 2019, 130 patients who underwent curative hepatectomy for hepatocellular carcinoma were enrolled. PNI was calculated. Its cutoff value was identified through receiver operating characteristic curve analysis. According to PNI, patients were divided into two groups. Univariate and multivariate analyses were performed to identify independent risk factors for recurrence.
RESULTS: The cutoff value of PNI was 52. In univariate analysis, alcoholic liver cirrhosis (p = 0.041), protein induced by vitamin K antagonist- II ≥ 200 (p = 0.012), indocyanine green retention test (ICG R15) >10% (p = 0.001), estimated blood loss ≥ 800 mL (p = 0.037), tumor size (p = 0.001), microvascular invasion (p = 0.023), T-stage (p = 0.001), and PNI < 52 (p = 0.001) were significant factors affecting the recurrence. In multivariate analysis, alcoholic liver cirrhosis (p = 0.046), ICG R15 >10% (p = 0.025), T-stage (p = 0.003), and PNI < 52 (p = 0.046) were independent prognostic factors for disease-free survival.
CONCLUSIONS: PNI, a nutritional and immunologic factor, is an independent prognostic factor that can predict the recurrence of hepatocellular carcinoma in patients undergoing a curative resection.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the 6th most common malignancy worldwide and the 2nd leading cause of cancer death [1]. According to the annual report of cancer statistics in Korea in 2016, HCC was the 6th most common cancer. However, its mortality rate was the second highest. There are many treatment modalities such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol injection, and radiation. However, curative resection and liver transplantation are still considered first-line treatment options [2]. Its long-term prognosis remains unsatisfactory. Its 5-year recurrence rate is approximately 50%–70% even after a curative resection [3,4]. The high recurrence incidence remains a major cause of death after a curative resection. Its well-known prognostic factors up to date include microvascular invasion, poor differentiation, multiple tumors, and tumor size [5-7]. Most patients with HCC have chronic liver diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV), and alcoholic liver cirrhosis. It is difficult to predict the prognosis of patients with only the tumor burden as prognosis is affected by impaired liver function related to underlying liver disease. Many studies have confirmed that the pathogenesis of HCC is associated with inflammation of the underlying chronic liver disease. Inflammation is an essential factor in tumor progression [8]. In addition, cancer cachexia has been observed in many patients with HCC. Furthermore, the nutritional status of patients is closely related to the function of the immune system and the inflammatory response. Initially, prognostic nutritional index (PNI) has been proposed to assess immunological and nutritional aspects of patients who undergo a gastrointestinal surgery [9]. Preoperative PNI can be calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Many studies have indicated that PNI is a prognostic factor for gastrointestinal malignancies [10]. However, there are limited data on screening HCC patients for malnutrition. Little data has been released on the prognostic value of PNI in these patients. Therefore, PNI was used in this retrospective cohort study of patients with HCC. It was found that PNI was a significant predictor of recurrence after a curative resection.

PATIENTS AND METHODS

Patients

Clinical data of patients who underwent hepatectomy for HCC between January 2007 and December 2019 at Dankook University Hospital were retrospectively reviewed. Only patients with complete follow-up information were included. Patients with evidence of infection or systemic inflammatory diseases were excluded. Patients who underwent locoregional therapy such as TACE and RFA before surgery and those who had HCC recurrence were also excluded. In addition, patients with combined hepatocellular cholangiocarcinoma were excluded from postoperative biopsy results. Five in-hospital deaths were also excluded. Curative hepatectomy was defined as complete removal of HCC without grossly or microscopically identifiable tumor residue on the resection margin. We collected data from clinical records, including basic patient demographics, concomitant diseases, complete blood count, biochemistry and liver function parameters, alpha-fetoprotein (AFP), prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II), HBV and HCV markers, T-stage, clinicopathologic parameters, and other tumor-related parameters for each patient. Detailed medical history, physical examination, and preoperative routine laboratory tests were performed at least 7 days prior to the surgery. The diagnosis of HCC was made based on preoperative radiological examination criteria and confirmed by postoperative pathological findings. Of 130 patients, 52 underwent major resections (over three segments) and 78 patients underwent minor resections. There were 84 anatomical resections and 46 non-anatomical resections.

Follow-up

Regular follow-up was conducted in the outpatient clinic. Monthly serum AFP and PIVKA-II tests were performed during the first three months after surgery. Chest radiography and contrast-enhanced computed tomography were performed at least every three months for the first two years. Patients were followed up with serological and imaging tests every six months during the first three to five years. Five years later, follow-up was performed annually. Tumor recurrence was diagnosed using imaging and laboratory tests. Patients with confirmed HCC recurrence underwent individualized treatment, including repeated liver resection, TACE, RFA, and liver transplantation. The median follow-up was 34.5 months (range, 2–157 months). The last follow-up date was in July 2020.

Ethical considerations

The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Dankook University Hospital (IRB No: DKUH 2021-01-017). The requirement for informed consent was waived because of the retrospective nature of this study.

Statistical analysis

To assess the sensitivity and specificity of PNI for predicting recurrence, we analyzed receiver operating characteristic (ROC) curve and identified the optimum cutoff value for PNI. We divided patients into two groups according to the cutoff value of the PNI. Continuous variables were represented as the median interquartile range and compared with a Mann–Whitney U-test. Categorical variables were expressed as counts (percentages) and compared with chi-square test or Fisher’s exact test when appropriate. Factors associated with recurrence-free survival were analyzed using univariate and multivariate logistic regression analyses. Disease-free survival (DFS) curve was calculated using the Kaplan–Meier method and compared using a log-rank test. All statistical analyses were performed using IBM SPSS version 26 (IBM Corp., Armonk, NY, USA).

RESULTS

The area under the ROC curve was 0.572. The optimal cutoff value of PNI was 51.85 (Fig. 1). Therefore, the optimum PNI cutoff value was set at 52. We defined 53 patients with PNI ≥ 52 as the high-PNI group and 77 patients with PNI < 52 as the low-PNI group. Associations between clinicopathological parameters and PNI are shown in Table 1. Albumin levels were higher in the high-PNI group with improved coagulation function. Results of indocyanine green retention test (ICG R15) for predicting residual liver function before surgery were found to be better in the high-PNI group than those in the low-PNI group, although the difference between the two groups was not significant. In the low-PNI group, there was more bleeding during surgery and more frequent blood transfusions. The tumor size was smaller in the high-PNI group. HCC recurred in 65 (50.0%) patients, including 17 patients (32.1%) in the high-PNI group and 48 patients (62.3%) in the low-PNI group.

Fig. 1

Receiver operating characteristic (ROC) curve. The area under the ROC curve is 0.572 (95% confidence interval: 0.47–0.67, p < 0.05) and the optimal cutoff value is 51.85.

Table 1

Characteristics of patients included in this study

Variable	PNI-high group (n = 53)	PNI-low group (n = 77)	p-value
Age (yr)	54 (33–80)	61 (39–83)	0.187
Male	44 (83.0)	67 (87.0)	0.616
Hepatitis			0.097
HBV	41 (77.4)	44 (57.1)
HCV	3 (5.7)	7 (9.1)
Alcohol	3 (5.7)	13 (16.9)
Child-Pugh			0.121
A	51 (96.2)	67 (87.0)
B	2 (3.8)	10 (13.0)
Comorbidity
Diabetes	42 (79.2)	50 (64.9)	0.116
Hypertension	34 (64.2)	48 (62.3)	0.855
Albumin (g/dL)	4.4 (3.7–5.2)	3.9 (2.3–4.8)	< 0.001
Lymphocyte (/mm3)	2,380 (1,650–6,760)	1,520 (490–2,620)	< 0.001
Platelet (×103/mm3)	170 (79–345)	156 (56–464)	0.913
PT INR	0.97 (0.86–1.85)	1.03 (0.83–1.61)	0.036
CRP (mg/dL)	0.15 (0.01–3.02)	0.26 (0.01–3.89)	0.150
ALT (U/L)	29 (10–164)	31 (4–137)	0.747
Total bilirubin (mg/dL)	0.5 (0.19–2.58)	0.6 (0.17–1.93)	0.455
AFP (ng/mL)	20.3 (0.6–15,000)	7.2 (0.5–11,340)	0.339
PIVKA-II (mAU/mL)	58 (10–33,726)	77 (9–48,555)	0.157
ICG R15 (%)	8.3 (1–22.7)	11.5 (1–32)	0.079
Estimated blood loss (mL)	400 (0–2,400)	600 (0–5,000)	0.017
Blood loss > 800 mL	11 (20.8)	28 (36.4)	0.079
Intraoperative transfusion	6 (11.3)	29 (37.7)	0.001
Operation time (min)	260 (95–580)	230 (65–985)	0.419
Operation method
Laparoscopic	23 (43.4)	23 (29.9)	0.137
Nonanatomic resection	17 (32.1)	29 (37.7)	0.692
Major resection[a)]	24 (45.3)	28 (36.4)	0.364
Size (cm)	2.7 (0.8–10)	3.5 (1–24)	0.012
Margin (mm)	11 (1–70)	10 (1–55)	0.367
Multiple tumor	9 (17.0)	8 (10.4)	0.299
Edmondson grade			0.398
Grade 1	4 (7.5)	10 (13.0)
Grade 2–4	49 (92.5)	67 (87.0)
Microvascular invasion	13 (24.5)	16 (20.8)	0.671
T-stage			0.055
1	31 (58.5)	41 (53.2)
2	18 (34.0)	17 (22.1)
3	0	4 (5.2)
4	4 (7.5)	15 (19.5)
Recurrence	17 (32.1)	48 (62.3)	0.001

Values are presented as median (interquartile range) or number (%).

PNI, prognostic nutritional index; HBV, hepatitis B virus; HCV, hepatitis C virus; PT INR, prothrombin time international normalized ratio; CRP, C-reactive protein; ALT, alanine aminotransferase; AFP, alpha fetoprotein; PIVKA II, prothrombin induced by vitamin K antagonist-II; ICG R15, indocyanine green retention test.

a)Resection > 3 segments.

A univariate analysis was performed to investigate factors affecting HCC recurrence. In the univariate analysis, alcoholic liver cirrhosis, PIVKA-II ≥ 200, ICG R15 > 10%, estimated blood loss ≥ 800 mL, tumor size, microvascular invasion, T-stage, and PNI < 52 were closely related to HCC recurrence after a curative resection (Table 2). Multivariate analysis showed that alcoholic liver cirrhosis (hazard ratio [HR]: 4.33, 95% confidence interval [CI]: 1.02–18.28, p = 0.046), ICG R15 >10% (HR: 1.10, 95% CI: 1.01–1.20, p = 0.025), T-stage (HR: 2.20, 95% CI: 1.31–3.70, p = 0.003), and PNI < 52 (HR: 2.60, 95% CI: 1.01–6.68, p = 0.046) were independently associated with HCC recurrence after a curative resection (Table 3). Cumulative DFS was estimated using the Kaplan–Meier method (Fig. 2). One-year, 3-year, and 5-year cumulative DFS rates were 92.1%, 69.7%, and 69.7% in the high-PNI group and 89.3%, 63.3%, and 40.2% in the low-PNI group, respectively (p = 0.011).

Table 2

Univariate analysis of disease-free survival

Variable	HR	95% CI	p-value
Age (≥ 70/< 70 yr)	0.82	0.34–1.95	0.661
Sex (male/female)	1.00	0.19–1.45	0.601
HBV (+/-)	0.62	0.29–1.28	0.198
HCV (+/-)	1.55	0.41–5.77	0.513
Alcohol (+/-)	3.45	1.05–11.34	0.041
Child-Pugh (B/A)	1.44	0.43–4.82	0.546
Diabetes (+/-)	1.82	0.84–3.93	0.125
Hypertension (+/-)	1.70	0.82–3.49	0.147
Albumin	0.72	0.34–1.51	0.392
Lymphocyte	1.00	0.99–1.00	0.350
Platelet (/mm3) (≤ 1.0 × 105/> 1.0 × 105)	1.16	0.39–3.41	0.784
PT INR (> 1.2/≤ 1.2)	3.20	0.62–16.50	0.164
CRP (mg/dL)	1.16	0.71–1.89	0.535
ALT (U/L)	1.01	0.99–1.02	0.088
Total bilirubin (mg/dL)	1.46	0.60–3.59	0.400
AFP (≥ 40/< 40)	1.61	0.77–3.34	0.198
PIVKA-II (≥ 200/< 200)	2.57	1.23–5.37	0.012
ICG R15 (> 10%/≤ 10%)	3.86	1.71–8.76	0.001
Estimated blood loss (≥ 800 mL/< 800 mL)	2.27	1.05–4.93	0.037
Intraoperative transfusion (+/-)	1.73	0.79–3.82	0.169
Operation time (≥ 300 min/< 300 min)	1.65	0.78–3.49	0.188
Laparoscopic resection (+/-)	0.58	0.28–1.20	0.144
Non-anatomical resection (+/-)	1.10	0.59–2.08	0.748
Major resection[a)] (+/-)	1.67	0.82–3.40	0.153
Size (cm)	1.23	1.08–1.40	0.001
Margin (≤ 10 mm/> 10 mm)	0.93	0.46–1.90	0.857
Multiple tumor (+/-)	2.00	0.69–5.78	0.199
Edmondson grade (1/2–4)	1.38	0.45–4.22	0.573
Microvascular invasion (+/-)	2.76	1.14–6.66	0.023
T-stage	2.07	1.38–3.10	0.001
PNI (≥ 52/< 52)	3.50	1.67–7.33	0.001

HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; PT INR, prothrombin time international normalized ratio; CRP, C-reactive protein; ALT, alanine aminotransferase; AFP, alpha fetoprotein; PIVKA-II, prothrombin induced by vitamin K antagonist-II; ICG R15, indocyanine green retention test; PNI, prognostic nutritional index.

a)Resection > 3 segments.

Table 3

Multivariate analysis of disease-free survival

Variable	HR	95% CI	p-value
Alcohol (+/-)	4.33	1.02–18.28	0.046
PIVKA-II (≥ 200/< 200)	1.03	0.34–3.13	0.948
ICG R15 (> 10%/≤ 10%)	1.10	1.01–1.20	0.025
Estimated blood loss (≥ 800 mL/< 800 mL)	1.45	0.52–4.06	0.476
Size (cm)	1.00	0.84–1.19	0.940
Microvascular invasion (+/-)	2.24	0.70–7.20	0.174
T-stage	2.20	1.31–3.70	0.003
PNI (≥ 52/< 52)	2.60	1.01–6.68	0.046

HR, hazard ratio; CI, confidence interval; PIVKA-II, prothrombin induced by vitamin K antagonist-II; ICG R15, indocyanine green retention test; PNI, prognostic nutritional index.

Fig. 2

Disease-free survival curves of patients in the high-PNI group compared to those in the low-PNI group. PNI, prognostic nutritional index.

DISCUSSION

Surgical resection for HCC is considered a safe operation due to its low mortality and morbidity. However, the prognosis of patients is poor because of the high recurrence rate after curative resection. Therefore, understanding and predicting recurrence are important for improving the prognosis of patients with HCC. There are three categories of factors involved in the recurrence after a curative resection of HCC [1]: 1) tumor factors such as tumor size, number, Edmondson–Steiner grade, and preoperative tumor markers [2]; 2) host factors such as the grade of hepatitis activity, presence of cirrhosis, and hepatitis viral load [3]; and 3) surgical factors such as surgical margin and extent of liver resection [11]. There have been many studies on tumor factors. Microvascular invasion is a predictor of tumor recurrence after curative resection. High AFP and multiple tumors also affect prognosis [5,6]. In addition, some studies have reported that HCV-related HCC has a poorer prognosis than HBV-related HCC [4]. It has been reported that satellite nodule, R1 margin resection, and non-anatomical resection can adversely affect recurrence [3]. In the present study, T-stage was found to be a significant risk factor for tumor recurrence after a curative resection.

Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis [8]. HCC was associated with HBV or HCV in most patients [8]. In that study, 95 of 130 patients (73%) were HBV or HCV related [8]. In our study, among 16 patients with alcoholic liver cirrhosis, 85% of patients had chronic hepatitis. In HCC patients, chronic inflammation might affect the recurrence and/or prognosis of cancer. Some studies have shown that these factors are linked to prognosis. Lymphocytes are immune factors of PNI. These cells play an important role in the recurrence and progression of HCC. A clinical study on resected specimens of HCC patients has shown that high densities of CD3(+) and CD8(+) T cells in the interior and margins of the tumor are significantly associated with a low rate of recurrence and a prolonged DFS [12]. These findings suggest that the host’s immune status such as lymphocyte infiltration into the tumor might play an important role in preventing tumor progression. The lymphocyte-to-monocyte ratio can predict survival outcomes in HBV-related HCC patients who undergo a curative hepatectomy [13]. The neutrophil-to-lymphocyte ratio and aspartate aminotransferase to platelet ratio can also predict recurrence after a curative resection [14,15]. In addition to the lymphocyte scoring system, the modified Glasgow prognostic score (mGPS) is a score that can confirm host’s inflammatory response. It is a combination of C-reactive protein and albumin levels. Indeed, a large cohort study has reported that mGPS can predict cancer survival independent of tumor sites [16]. According to these studies, the host inflammatory response can affect both recurrence and survival.

Nutrition has been linked to the prognosis of malignant tumors. Malnutrition has also been reported as an important prognostic factor in patients with HCC [17]. Furthermore, malnutrition is a risk factor for postoperative complications after hepatectomy in patients with HCC [18]. Although there are several scoring systems to determine the patient’s nutritional status before surgery, PNI is simple. PNI consists of albumin level and lymphocytes, which may reflect a balance between pro-tumor inflammatory status and nutritional status. In addition, albumin, a component of PNI, can reflect protein synthesis disorders following a chronic liver disease of HCC. In a meta-analysis, preoperative PNI is also a prognostic marker in patients with HCC [19,20]. According to the study by Ji et al. [21], PNI and body mass index can be used as important biomarkers to screen patients with early stage HCC for high risk of recurrence and death. One study has shown that PNI is a useful marker to predict survival of HCC patients treated with sorafenib [22]. Moreover, postoperative PNI, not preoperative PNI, could predict survival of patients with HCC after a surgical resection [23]. In the present study, PNI was confirmed to be an independent predictor of recurrence after a curative resection with alcoholic liver cirrhosis, ICG R15, and T-stage. In particular, alcoholic liver cirrhosis was identified as an independent prognostic factor. Most alcoholic liver cirrhosis patients are thought to be have poor nutrition.

ICG R15 is a common parameter for preoperative assessment of preserved hepatic function [24]. ICG R15 has been reported to be an early indicator of hepatic dysfunction. It has been used preoperatively to plan the extent of partial hepatectomy by predicting the risk of dysfunction after surgery. ICG R15 with a cutoff value of 10% as an upper limit of normal has been widely used in clinical practice in Korea. In the present study, ICG R15 > 10% was identified as an independent prognostic factor for DFS. As albumin, lymphocyte count, and ICG R15 are routine tests performed in clinical practice, the assessment of their values can be used to predict recurrence after surgery.

Our study has some limitations. First, the sample size was small because this was a retrospective single-center study. Second, selection bias was inevitable. It might have influenced the analysis because we selected only patients who had undergone a curative resection. Third, PNI did not affect survival. We investigated the survival curve using the Kaplan–Meier method. The p-value was 0.067, which was not statistically significant. Thus, large-scale studies should be conducted in the future.

In summary, our study examined risk factors affecting recurrence after curative resection for HCC. Patients with preoperative low-PNI, ICG R15 > 10%, alcoholic liver cirrhosis, and advanced T-stage had more recurrence after a curative resection. Our findings could be used to identify patients at risk of recurrence after hepatectomy and help them receive necessary treatment to improve their survival. However, more extensive cohort studies need to be conducted in the future to validate the clinical usefulness of PNI and other factors as predictive markers for recurrence in HCC.